Merck Rally Shows How to Defeat Key Patent Cliff Risks

Key Moments

Patent Worries Weigh on Pharma, but Merck Breaks Away

Large-cap pharmaceutical names have been under sustained pressure as investors focus on looming patent expirations for foundational drugs. The 2028 loss of exclusivity for Keytruda – currently the world’s best-selling oncology treatment – has been central to that concern, dampening sentiment around companies such as Bristol-Myers Squibb (NYSE:BMY) and Pfizer (NYSE:PFE).

Merck & Co. (NYSE:MRK), however, has diverged sharply from that narrative. The stock has climbed 42.3% since January to trade near $146.73. While much of the market views patent expirations as abrupt revenue cliffs, Merck’s recent performance illustrates how early planning and disciplined execution can diffuse that risk well in advance.

AI-Driven Portfolio Strategy and Merck’s Inclusion

InvestingPro’s ProPicks AI models are designed to identify cases where market anxiety obscures the underlying strength of a company’s commercial trajectory. The system added Merck to the Dominate the Dow strategy in January at $103.13.

In the active November portfolio, Merck appears alongside other resilient blue chips, including an industrial power generation leader, a commercial oncology biopharma developer, and a key national telecom operator.

From Cliff to Glide Path: Managing Keytruda’s Lifecycle

Third-quarter results underscored why institutional investors have continued to support Merck. The company reported revenue of $18.1 billion, topping consensus estimates of $17.28 billion, and adjusted earnings per share of $2.49 versus expectations of $2.09. On the back of this performance, management lifted full-year 2026 revenue guidance to a range of $66.8 billion to $67.3 billion.

Keytruda remained a major growth driver, with sales increasing 6% year-over-year to $8.6 billion. At the same time, Merck is actively reshaping the franchise’s durability. Keytruda Qlex, a subcutaneous formulation delivered via injection rather than a multi-hour intravenous infusion, extends intellectual property protections well into the 2030s. Management is aiming to convert 30% to 40% of U.S. patients to this new formulation by the end of 2027, effectively smoothing the anticipated revenue decline into a more measured transition.

Pipeline Highlights: Winrevair and Intismeran

Merck’s strategy is not limited to defending Keytruda’s position. New therapies are building additional layers of growth around the core franchise.

• Winrevair – An important therapy for pulmonary arterial hypertension, Winrevair posted a 94% year-over-year revenue increase to $694 million in the quarter. This acceleration was supported by an expanded FDA label that allows for earlier intervention in the treatment pathway.
• Intismeran – In oncology, the personalized cancer vaccine intismeran, developed in partnership with Moderna, demonstrated compelling data. In Phase 3 trials, the combination of intismeran with Keytruda reduced the risk of melanoma recurrence or death by 42%. A regulatory filing is planned for 2027.

With these launches and life-cycle extensions, management expects total company revenues to exceed $70 billion by the mid-2030s.

Financial Strength, Valuation, and Capital Returns

Merck’s commercial momentum is supported by strong internal cash generation. Over the trailing twelve months, the company produced $18.7 billion in operating cash flow. This underpins a 4.07% free cash flow yield, which more than supports its 2.31% dividend yield.

The dividend profile has been consistent, with 15 consecutive years of dividend increases. Merck also plans approximately $3 billion in share repurchases for 2026. Within InvestingPro’s Financial Health framework, Merck is rated as “Good,” reflecting robust cash flow coverage of its debt obligations.

Valuation Dynamics and Street Sentiment

Merck’s current headline valuation of 52.2 times trailing earnings is influenced by what has been a trough year for reported accounting profits. Consensus projections compiled on InvestingPro point to a rapid multiple compression, with the stock valued at 16.3 times expected 2027 earnings.

Management anticipates more than $2 billion in 2027 revenue pressure from older products facing generic competition. Even so, the breadth and progress of the pipeline provide considerable support for future earnings.

Analysts broadly reflect this constructive outlook. The median target price stands at $161.53, suggesting further upside from current levels. Following third-quarter results, JPMorgan set a price objective of $175, while Morgan Stanley issued a target of $174.

Selected Merck Metrics and Outlook